Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2961-2965

  Pettit, Robin K ^a   Pettit, George R ^a   Hazen, Kevin C ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; DOLASTATIN 10; FLUCONAZOLE; PEPTIDE DERIVATIVE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DIFFUSION; DILUTION; DRUG RESISTANCE; DRUG STRUCTURE; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; SERUM;

EID: 0031751633     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2961     Document Type: Article

References (21)

1. Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p. 52-111. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
2. Bagniewski, P. G., J. M. Reid, H. C. Pitot, J. A. Sloan, and M. M. Ames. 1997. Pharmacokinetics of dolastatin 10 in adult patients with solid tumors, abstr. 1492. In Proceedings of the American Association for Cancer Research, American Association for Cancer Research, Philadelphia, Pa.
3. Bai, R., G. R. Pettit, and E. Hamel. 1990. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem. 265(28):17141-17149.
4. Bai, R., G. R. Pettit, and E. Hamel. 1990. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: inhibition or tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 39(12):1941-1949.
5. Beckwith, M., W. J. Urba, and D. L. Longo. 1993. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J. Natl. Cancer Inst. 85(6):483-488.
6. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, T. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
7. Jessup, C. J., T. L. Wallace, and M. A. Ghannoum. 1997. Evaluation of antifungal activity of nyotran against various pathogenic fungi, poster F-88. In 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada.
8. Maki, A., H. Diwakaran, B. Redman, S. Al-Asfar, G. R. Pettit, R. M. Mohammad, and A. Al-Katib. 1995. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs 6:392-397.
9. McElroy, E. A., H. C. Pitot, C. Erlichman, et al. 1997. Phase I trial of dolastatin 10 in patients with advanced solid tumors, abstr. 782. In Proceedings ot the American Society of Clinical Oncology. American Society of Clinical Oncology, Chicago, Ill.
10. Meunier, F. 1996. Current clinical issues on mycoses in neutropenic patients. Int. J. Antimicrob. Agents 6:135-140.
11. National Committee for Clinical Laboratory Standards. 1997. Performance standards for Antimicrobial disk susceptibility tests-sixth edition: approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Newman, R. A., A. Fuentes, J. M. Covey, and J. A. Benvenuto. 1994. Pre-clinical pharmacology of the natural marine product dolastatin 10 (NSC 376128). Drug Metab. Dispos. 22(3):428-432.
14. Pettit, G. R. 1997. The dolastatins, p. 1-79. In W. Herz, G. W. Kirby, R. E. Moore, W. Steglich, and C. Tamm (ed.), Progress in the chemistry of organic natural products - 70th ed. Springer-Verlag, New York, N.Y.
15. Pettit, G. R., Y. Kamano, C. L. Herald, A. A. Tuinman, F. E. Boettner, H. Kizu, J. M. Schmidt, L. Baczynskyj, K. B. Tomer, and R. Bontems. 1987. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc. 109:6883-6885.
16. Pettit, G. R., S. B. Singh, F. Hogan, P. Lloyd-Williams, D. L. Herald, D. D. Burkett, and P. J. Clewlow. 1984. The absolute configuration and synthesis of natural (-)-dolastatin 10. J. Am. Chem. Soc. 111:5463-5465.
17. Pettit, G. R., J. K. Srirangam, J. Barkóczy, M. D. Williams, M. R. Boyd, E. Hamel, R. K. Pettit, F. Hogan, R. Bai, J. Chapuis, S. C. McAllister, and J. M. Schmidt. 1948. Antineoplastic agents 365. Dolastatin 10 SAR probes. Anti-Cancer Drug Design 13:243-277.
18. Pettit, G. R., J. K. Srirangam, S. B. Singh, M. D. Williams, D. L. Herald, J. Barkóczy, D. Kantoci, and F. Hogan. 1996. Dolastatins 24. Synthesis of (-)-dolastatin 10. X-ray molecular structure of N,N-dimethylvalyl-valyl-1. dolaisoleuine tert-butyl ester. J. Chem. Soc. Perkin Trans, 1. 5:859-863.
19. Pettit, G. R., J. K. Srirangam, and D. Kantoci. September 1997. U. S. patent 5,663,149.
20. Samonis, G., and D. Bafaloukos. 1992. Fungal infections in cancer patients: an escalating problem. In Vivo 6:183-194.
21. Tran, H. T., R. A. Newman, D. E. Beck, et al. 1997. A phase I, pharmacokinetic/pharmacodynamic study of dolastatin 10 in adult patients with advanced solid tumors, abstr. 2056. In Proceedings of the American Association for Cancer Research. American Association for Cancer Research, Philadelphia, Pa.